Increased mortality in digoxin-treated subjects has been demonstrated in patients with recent myocardial infarction. Those with congestive heart failure (CHF) due to causes other than myocardial infarction seem to be free from this effect. No information is currently available concerning mortality in elderly people who are frequently prescribed digitalis even in the absence of CHF. The aim of this study was to investigate whether subjects improperly receiving digoxin were worse off than those not receiving this drug. This analysis is a part of CASTEL, a population-based prospective study that has enrolled a cohort of 2,254 subjects aged65 years. CHF was diagnosed in 187 subjects and atrial fibrillation (AF) in 90. The remaining 1,977 were free from CHF and in sinus rhythm, but 447 were treated with digitalis. Cumulative mortality and morbid events by digitalis treatment were calculated in all these categories.
An increased mortality in digoxin-treated subjects has actually been demonstrated in patients with recent myocardial infarction3-9) (MI) but not in those with congestive heart failure (CHF) due to other causes. No information is available on the impact of digitalis on mortality and morbidity in subjects without CHF, when it is frequently prescribed particularly in the elderly10-12) on the belief that it might improve the performance of a "tired" heart. Even if this does not represent a good practice, it is nevertheless a reality, and the possibility that it worsens the outcome should be examined closely.
In the present population-based study, longitudinal data from a cohort of elderly subjects has been evaluated in order to determine whether those improperly receiving digoxin had a worse survival or a greater frequency of events in comparison to those who did not receive it.
METHODS
General protocol: The analysis described herein is a part of the CArdiovascular STudy in the ELderly (CASTEL), whose protocol has been described elsewhere.13) Briefly, the CASTEL is a population-based, prospective, intervention study enrolling a cohort of 2,254 subjects aged 65 years or over, representing 73% of all elderly subjects from the Northern Italian town of Castelfranco Veneto.
During the initial survey performed in 1983-85, sitting blood pressure was measured in triplicate at 15-min intervals 3 times at 1-month intervals, and only the average of the last 2 of the 9 measurements was taken into consideration in order to avoid the effects of an alert reaction. Heart rate was taken at the end of each BP measurement, and the average of the last two measurements was considered for the analysis of the data.
Historical data were recorded by means of a Rose's questionnaire. Body mass index (BM1) was calculated as the ratio between weight and squared height. All subjects were screened for albuminuria with a dipstick using a random morning urine sample; urine infection was previously excluded. Maximal expiratory flow in 1 second (FEV1) was measured and reference values individually calculated.14) In a random subset of 504 subjects V1, left ventricular enddiastolic diameters and thicknesses were measured, and end-diastolic left ventricular volumes, stroke volume, and fractional shortening were calculated.15) Approach to CHF: All subjects with clinical, radiological, or echocardiographic signs of CHF were treated with diuretics (furosemide 25 to 100mg/day or hydrochlorothiazide 25 to 50mg/day) and ACE-inhibitors (5 to 20mg/day of enalapril or equivalent doses of other compounds). Class NYHA16) 1 was recorded in 134 subjects, class 2 in 35, class 3 in 17 and class 4 in 1. Subjects free from CHF and in sinus rhythm (n=1,977): This category included subjects with a left ventricular ejection fraction of 45% or higher, no clinical/radiological sign of CHF, and no supraventricular arrhythmias, and represented the majority of the population; 438 were treated with digoxin, reflecting the current way of prescribing digitalis in the elderly without a clear clinical indication.10-12) Their general characteristics are summarised in Table I . These subjects had, in comparison to the others, a more advanced age, higher systolic BP and uric acid, a worse glucose tolerance and pulmonary function, and a greater prevalence of historical angina pectotis, MI and transient ischaemic attack. All statistics comparing digoxin-treated and untreated subjects were therefore adjusted for these confounders. Other characteristics, including systolic func- predictor of overall survival (Table II) . The cumulative survival curves during the 12 years of follow-up (Figure 1 , upper panel) confirmed that digitalis-treated subjects had a worse survival than those not receiving this drug. Twelve-year mortality rate was 58.9% in the former and 40.5% in the latter (p<0.0001; adjusted RR of the digitalis treatment 1.27, C.I. 1.071.48). "Digitalis treatment" was also accepted in the Cox equation of the cardiovascular survival (Table II) . Adjusted RR of the digitalis treatment was 1.39 (C.I. 1.121.75). Figure 1 (lower panel) shows cumulative cardiovascular survival during the follow-up. Cardiovascular mortality was due to myocardial infarction in 68 cases, cardiac arrest in 60, CHF in 172, stroke in 85, and other causes in 34. Cardiovascular mortality rate was constantly higher in subjects receiving digoxin (21.5%) than in those who did not receive this drug (17.7%, p<0.0001) and, except for myocardial infarction, all differences between digoxin-treated and untreated subjects were statistically significant ( Figure 2 ). The incidence of non-fatal CHF was significantly higher in subjects taking digoxin than in the others (Figure 3, left panel) and the incidences of the other morbid events were insignificantly higher (3.9 vs. 2.4% for MI, 6.3 vs. 2.4% for angina, 5.3 vs. 4.4% for stroke). The question is whether by doing so survival might improve. The CASTEL was initially born with the aim of studying hypertension and its treatment in the elderly, and the effect of digitalis on mortality was not specified in advance as a study outcome. Nevertheless, the data on digitalis treatment seemed interesting enough to induce the CASTEL Study Group to present the results summarised herein. In the population-based CASTEL project, digoxin treatment had no effect on mortality in elderly patients with CHF or atrial fibrillation, two generally accepted indications of digitalis. 38, 39) As this is in agreement with previous studies, this topic will not be further discussed here.
In elderly subjects without signs of CHF and in sinus rhythm, digoxin significantly reduced survival. The obvious possibility that this was simply attributable, like in the MILIS,20) "to more base-line characteristics predictive of mortality" in the digoxin-treated patients than in the counterpart was excluded by adjusting for all confounders. This confirms that a negative prognostic impact of digoxin exists independently of the presence of other risk factors, and is mainly due to a significant increase in cardiovascular fatal events and particularly to a greater frequency of cardiac arrest, fatal CHF, or stroke. Fatal MI was also more frequent in digoxin-treated elderly subjects, although statistical significance was not reached.
Significant excess in sudden death in subjects receiving cardiac glycosides has been previously described by Sweeney et al. in the post-infarction periods40 and by Olson et al. in the case of toxicity.41) Digitalis can notoriously initiate ventricular arrhythmias6,41,42) by increasing ventricular automaticity. As this was not observed in decompensated CHF,18) it is likely that in these patients this dangerous potential is counterbalanced by an improvement in systolic function and by a depression of the adrenergic drive. 43) As inotropic agents increase oxygen consumption,44) there are also theoretical reasons for cardiac glycosides to worsen ischaemia9) and increase CAD mortality. This has been shown in patients with CAD or with a recent MI, where digoxin sometimes represented an independent determinant of death.3,9) In our experience, however, a worsening of cardiovascular survival was experienced independently of the presence of CAD or history of MI.
Although the subjects of the main study group were, by definition, free from CHF at the initial screening, 202 of them developed CHF during the follow-up and 172 died of CHF. Both the incidence of CHF and the frequency of CHF deaths were similar in digoxin-treated and untreated subjects. The only other data relative to this issue are those recorded by Georghiade and Zarowitz18 who found clinical worsening in 30% of patients with chronic CHF, and those by Leor et al.6) who described an increased incidence of CHF in post-MI patients treated with digoxin.
We also found that both CHF mortality and morbidity were greater in digoxin-treated than in the untreated subjects, thus showing that digoxin not only was incapable of preventing CHF, but was also suspected of worsening CHF outcome. As systolic function at entry was comparable in digoxin-treated and untreated subjects and statistics were adjusted for all other confounding variables, this unfavourable effect must be attributed to digoxin itself. The only similar previous finding is that of the DIG study,28) where patients with chronic CHF were however treated: here, a neutral effect of digitalis on medium-term CHF mortality was observed (RR 0.86).
The significantly higher stroke mortality in our digoxin-treated subjects is difficult to interpret since the number of deaths was limited (n=85). The only data in this respect are those collected by others in patients with atrial fibrillation, which is not our case. The possibility that an excessive slowing of heart rate induced by digoxin with a consequent fall in cardiac output might have favoured stroke is only matter for speculation.
In conclusion, our results demonstrate that digoxin, when not indicated by CHF or AF, should not be prescribed in the elderly because it could increase the risk of mortality and is unable to prevent CHF. Even in patients with CHF or AF, no protective effect is detectable. Physicians should therefore be discouraged from using digitalis indiscriminately in elderly subjects without or with only minimal signs of CHF.
